Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Synagis Stories

2013-09-18 23:04:40

Reportbuyer.com just published a new market research report: Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission...

2013-09-18 23:02:47

Reportbuyer.com just published a new market research report: PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread...

2013-07-16 12:32:50

COLLEGE PARK, Md., July 16, 2013 /PRNewswire-USNewswire/ -- The Maryland Industrial Partnerships (MIPS) program, an initiative of the Maryland Technology Enterprise Institute (Mtech) in the A. James Clark School of Engineering at the University of Maryland, has awarded $3.8 million to 17 teams combining Maryland companies with university researchers to bring technology products closer to market, program officials announce today. (Logo:...

2013-01-02 08:23:23

NEW YORK, Jan. 2, 2013 /PRNewswire/ -- AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company With a rich, 125-year heritage of developing...

2012-10-03 06:25:54

GAITHERSBURG, Md., Oct. 3, 2012 /PRNewswire/ -- MedImmune, the biologics arm of AstraZeneca, today announced that the Journal of Medical Economics has published a study that shows Synagis® (palivizumab) is within the acceptable range of cost effectiveness. Specifically, the study relates to Synagis' reduction in hospitalizations due to serious respiratory syncytial virus (RSV) disease among eligible preterm infant populations covered by Medicaid and private insurers in the United States...

2012-05-01 06:27:25

BOSTON, May 1, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced results from a new retrospective database cohort study of 8,443 high-risk infants receiving palivizumab in Medicaid programs across 12 states. Approximately 67% of infants were non-compliant with palivizumab. Non-compliance with the FDA-approved dosing of Synagis® (palivizumab), defined as not receiving at least 5 doses or having dosing gaps, significantly increased likelihood of...

2010-01-29 13:00:00

GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of Pediatrics. Motavizumab is an investigational monoclonal antibody (MAb) being evaluated by the FDA for its potential to prevent serious disease caused by respiratory syncytial virus (RSV)...

2009-06-29 11:19:00

Company Increases Eligibility to Its Patient Assistance Program to 400 Percent of Federal Poverty; as Many as 75 Percent of U.S. Households May Now Qualify for This Program GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune today announced the expansion of the MedImmune Assistance Program for Synagis(R) (palivizumab) designed to provide the antibody at no cost to qualifying patients who lack health insurance and whose family household income falls within a certain range of the Federal...

2008-10-11 12:00:09

To: NATIONAL EDITORS Contact: Media - Tor Constantino, +1-301-398-5801, Investors - Peter Vozzo, +1-301-398-4358, both of MedImmune BOSTON, Oct. 11 /PRNewswire-USNewswire/ -- MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2008 National Conference & Exhibition that add to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of viral respiratory infection among preterm...